Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 1;37(1):40-47.
doi: 10.1097/WNN.0000000000000359.

Barriers to Alzheimer Disease Clinical Trial Participation in a Minority Population

Anson Y Lee  1   2 , Julia R Jahansooz  1   2 , Darrell Guittu  1 , Rexton Suzuki  1 , Lauren Pak  1 , Kyle M Ishikawa  2   3 , Connor Goo  1   2 , John J Chen  2   3 , Enrique Carrazana  1   2 , Jason Viereck  1   2   3 , Kore K Liow  1   2   3
Affiliations

Barriers to Alzheimer Disease Clinical Trial Participation in a Minority Population

Anson Y Lee et al. Cogn Behav Neurol. .

Abstract

Background: Alzheimer disease (AD), the most common neurodegenerative disorder in the United States, disproportionately burdens minority populations.

Objective: To explore barriers to AD clinical trial participation by Asian and Native Hawaiian patients diagnosed with AD or mild cognitive impairment.

Method: We surveyed 187 patients with a Mini-Mental State Examination score ≥14 between January 2022 and June 2022. The score cutoff for clinical trial eligibility was set by the institution. Individuals also completed a 15-question telephone survey that assessed demographics, barriers to clinical trial participation, and clinical trial improvement methods.

Results: Forty-nine patients responded, with a response rate of 26%. Asian and Native Hawaiian patients were less likely than White patients to participate in AD trials. The main barrier to participation was a lack of information about AD trials. Providing additional information regarding AD trials to patients and family members were listed as the top two reasons patients would consider participating in a clinical trial.

Conclusion: Insufficient information about AD clinical trials is the primary barrier to participation among Asian and Native Hawaiian patients, followed by difficulty coordinating transportation and, in the case of Asians, the time required for clinical trials. Increased outreach, education, and assistance with logistics in these populations should be pursued to improve rates of participation in clinical trials.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Alexopoulos P, Skondra M, Kontogianni E, et al. 2021. Validation of the cognitive telephone screening instruments COGTEL and COGTEL+ in identifying clinically diagnosed neurocognitive disorder due to Alzheimer’s disease in a naturalistic clinical setting. J Alzheimers Dis. 83:259–268. doi:10.3233/JAD-210477 - DOI - PMC - PubMed
    1. Andrade NN, Bell CK. 2011. The Hawaiians. In: McDermott JF, Andrade NN, eds. People and Cultures of Hawai’i: The Evolution of Culture and Ethnicity. Honolulu, Hawaii: University of Hawai’i Press; 1–31.
    1. Bonk J. 2010. A road map for the recruitment and retention of older adult participants for longitudinal studies. J Am Geriatr Soc. 58:303–307. doi:10.1111/j.1532-5415.2010.02937.x - DOI - PubMed
    1. Calderón JL, Baker RS, Fabrega H, et al. 2006. An ethno-medical perspective on research participation: a qualitative pilot study. MedGenMed. 8:23. - PMC - PubMed
    1. Clark LT, Watkins L, Piña IL, et al. 2019. Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 44:148–172. doi:10.1016/j.cpcardiol.2018.11.002 - DOI - PubMed